Repros Therapeutics Inc.® (Nasdaq: RPRX) today reported that it has electronically submitted a New Drug Application (NDA) to the U.S ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE